145 related articles for article (PubMed ID: 33605454)
1. Do dimethyl fumarate and nicotinic acid elicit common, potentially HCA
Dubrall D; Pflock R; Kosinska J; Schmid M; Bleich M; Himmerkus N; Offermanns S; Schwaninger M; Sachs B
Br J Clin Pharmacol; 2021 Oct; 87(10):3813-3824. PubMed ID: 33605454
[TBL] [Abstract][Full Text] [Related]
2. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A
Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717
[TBL] [Abstract][Full Text] [Related]
3. Dimethyl fumarate downregulates the immune response through the HCA
von Glehn F; Dias-Carneiro RPC; Moraes AS; Farias AS; Silva VAPG; Oliveira FTM; Silva CEBG; de Carvalho F; Rahal E; Baecher-Allan C; Santos LMB
Mult Scler Relat Disord; 2018 Jul; 23():46-50. PubMed ID: 29763776
[TBL] [Abstract][Full Text] [Related]
4. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006.
Aagaard L; Nielsen LH; Hansen EH
Drug Saf; 2009; 32(11):1067-74. PubMed ID: 19810778
[TBL] [Abstract][Full Text] [Related]
5. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
[TBL] [Abstract][Full Text] [Related]
6. The Immunometabolomic Interface Receptor Hydroxycarboxylic Acid Receptor 2 Mediates the Therapeutic Effects of Dimethyl Fumarate in Autoantibody-Induced Skin Inflammation.
Wannick M; Assmann JC; Vielhauer JF; Offermanns S; Zillikens D; Sadik CD; Schwaninger M
Front Immunol; 2018; 9():1890. PubMed ID: 30154797
[TBL] [Abstract][Full Text] [Related]
7. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
Castillon G; Salvo F; Moride Y
Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
[TBL] [Abstract][Full Text] [Related]
8. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
Inácio P; Airaksinen M; Cavaco A
Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
[TBL] [Abstract][Full Text] [Related]
9. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.
Wu L; Ingle T; Liu Z; Zhao-Wong A; Harris S; Thakkar S; Zhou G; Yang J; Xu J; Mehta D; Ge W; Tong W; Fang H
BMC Bioinformatics; 2019 Mar; 20(Suppl 2):97. PubMed ID: 30871458
[TBL] [Abstract][Full Text] [Related]
10. Patient Reporting in the EU: Analysis of EudraVigilance Data.
Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P
Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320
[TBL] [Abstract][Full Text] [Related]
11. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
[TBL] [Abstract][Full Text] [Related]
12. Identification and comparison of sex-specific serious adverse drug reactions in spontaneous reports and systematically collected reports (ADRED).
Christ P; Dubrall D; Just KS; Lewke B; Below M; Stingl JC; Schmid M; Sachs B
Br J Clin Pharmacol; 2024 Mar; 90(3):776-792. PubMed ID: 37897066
[TBL] [Abstract][Full Text] [Related]
13. Persisting lymphopenia and dimethyl fumarate: A clinical commentary.
Diem L; Chan A
Mult Scler; 2021 Jul; 27(8):1309-1310. PubMed ID: 33620267
[TBL] [Abstract][Full Text] [Related]
14. Adverse drug reactions reported by consumers for nervous system medications in Europe 2007 to 2011.
Aagaard L; Hansen EH
BMC Pharmacol Toxicol; 2013 Jun; 14():30. PubMed ID: 23763896
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
16. Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011.
Aagaard L; Hansen EH
Int J Clin Pharm; 2014 Dec; 36(6):1222-9. PubMed ID: 25288145
[TBL] [Abstract][Full Text] [Related]
17. Monitoring drug safety in Astrakhan, Russia.
Kirilochev OO; Dorfman IP; Umerova AR
Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
[TBL] [Abstract][Full Text] [Related]
18. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy.
Leone R; Magro L; Moretti U; Cutroneo P; Moschini M; Motola D; Tuccori M; Conforti A
Drug Saf; 2010 Aug; 33(8):667-75. PubMed ID: 20635825
[TBL] [Abstract][Full Text] [Related]
19. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).
Thiessard F; Roux E; Miremont-Salamé G; Fourrier-Réglat A; Haramburu F; Tubert-Bitter P; Bégaud B
Drug Saf; 2005; 28(8):731-40. PubMed ID: 16048358
[TBL] [Abstract][Full Text] [Related]
20. Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.
Kowalec K; Kingwell E; Carruthers R; Marrie RA; Bernatsky S; Traboulsee A; Ross CJD; Carleton B; Tremlett H
BMJ Open; 2017 Jun; 7(5):e016276. PubMed ID: 28576902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
